Company Profile

Reliable Biopharmaceutical Corporation (AKA: Reliable Chemical Company~rbc)
Profile last edited on: 6/28/17      CAGE: 4Z6F1      UEI: EA8BTQL6LMZ3

Business Identifier: Active Pharmaceutical Ingredients (APIs) and High Purity Ingredients (HPIs) for pharmaceuticals and biologics
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1945 Walton Road
St Louis, MO 63114
   (314) 429-7700
Location: Multiple
Congr. District: 01
County: St. Louis

Public Profile

In November 2016, it was announced that Reliable Biiopharmaceiticals had beenacquired by VWR International (NASDAQ: VWR), Formerly doing business as the Reliable Chemical Company, Reliable Biopharmaceutical Corporation is involved in the development and manufacture of active pharmaceutical and high purity ingredients for pharmaceutical, biopharmaceutical, generic pharmaceutical, biotechnology, and cosmetic companies. The company manufacture cGMP controls for high purity inactive ingredients, including excipients, enzymes, buffers, and surfactants for use in intermediate processing and purification of biologic drugs. In addition, it manufactures critical processing aids, cosmeceuticals, and diagnostic components. Further, the company provides analytical, compliance, patents, process development, and regulatory services. Its products are used in generic injectable drugs for the treatment of cancer, heart disease, hypertension, anxiety, and other serious and life threatening illnesses.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $134,076
Project Title: New Inotropic Agents for the Treatment of Heart Failure
2002 1 NIH $100,000
Project Title: Oligonucleotides as Prodrugs for Anticancer Drugs
2000 2 NIH $747,301
Project Title: Synthesis and testing of a new class of heparingoids
1993 1 NIH $50,000
Project Title: Regulators of fibroblast growth factor activity
1993 1 NIH $50,000
Project Title: Synthesis of oxidant free potassium lactobionate

Key People / Management

  David Feldker -- President and CEO

  Phillip J Anevski -- Vice President of Pharmaceutical Manufacturing

  The late William G Ash -- Founder

  Bruce T Liang

  Umashanker Sampath

  Joseph A Toce -- Executive Vice President